ResMed is a wide-moat medical devices company with a perfect Piotroski F-Score of 9 out of 9, 25% return on equity, and four consecutive earnings beats, currently experiencing a technical downtrend that creates an accumulation opportunity for investors with a 12-to-18 month horizon.
Thesis pillars
- Wide Moat Compounder Quality→Stable
- Perfect Earnings Beat Streak→Stable
- Technical Downtrend Accumulation Window↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
ResMed Inc. (RMD) Stock Analysis
Temporary headwind edge
Healthcare · Medical Instruments & Supplies
Wait for pullback to $204.24. At $218.27 the A.R:R is 0.3:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $204.24 (Rr Min Solve Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Geographic: manufacturing outside the U.S.; Analyst target reached - limited upside remaining.
ResMed designs cloud-connected medical devices and software to treat obstructive sleep apnea, COPD, and other chronic respiratory conditions, plus residential-care management software for home health, hospice, and skilled-nursing providers, selling in more than 140 countries... Read more
Wait for pullback to $204.24. At $218.27 the A.R:R is 0.3:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $204.24 (Rr Min Solve Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Geographic: manufacturing outside the U.S.; Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Wide-moat business. Accumulate on weakness. Score 5.7/10, moderate confidence.
Passes 5/9 gates (clean insider activity, news events none recent, earnings proximity 46d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: moderate.
About ResMed Inc.
About ResMed Inc.
ResMed's cloud-connected AirView platform serves more than 30 million sleep-apnea and respiratory patients worldwide, while its Residential Care Software supports providers managing more than 160 million individual patient accounts; sales in combined Europe, Asia, and other regions outside the U.S. made up approximately 36% of net revenue in both fiscal 2025 and fiscal 2024. The company's device portfolio spans CPAP and bilevel systems, including the AirCurve 11 Series, alongside diagnostic tools such as NightOwl and ApneaLink Air.
ResMed earns revenue from device sales — CPAP and bilevel systems, high-flow therapy devices, ventilators, masks, and accessories — sold through wholly owned subsidiaries and independent distributors, plus recurring cloud-service and software revenue from its Residential Care Software business serving home medical equipment, hospice, and skilled-nursing customers. The company manufactures substantially all of its products outside the U.S. while selling in more than 140 countries, exposing it to tariff, currency, and cross-border supply-chain risk; U.S. tariffs announced in 2025 and potential retaliatory measures are cited as a specific cost pressure on components and finished goods. Reimbursement depends on government and private insurance plans covering CPAP and ventilation therapy, and ResMed competes against pharmaceutical alternatives such as GLP-1 drugs as well as device rivals including Philips, whose flow-generator recall and consent decree have temporarily reduced its competitive presence in the U.S. market. In May 2025, the company acquired VirtuOx, an independent diagnostic testing facility, to expand home-based sleep and respiratory diagnostics.
Show full overview
Two 2025-vintage risk factors point to a widening regulatory and trade perimeter around ResMed's supply chain: the 10-K discloses that the company manufactures substantially all of its products outside the U.S. just as new and threatened U.S. and retaliatory tariffs target cross-border medical-device trade, and separately warns that the May 2025 acquisition of VirtuOx subjects ResMed to new areas of direct federal healthcare oversight it did not previously carry as a device maker. Together, a foreign-manufactured device book meeting tariff exposure and a diagnostics unit meeting new federal oversight represent two distinct, dated expansions of ResMed's regulatory footprint beyond its historical FDA device-clearance risk.
See also: Healthcare · Medical Instruments & Supplies
From ResMed Inc.'s most recent 10-K filing, extracted September 6, 2026.
Recent developments
updated 2026-09-13Recent Developments — ResMed Inc.
Latest news
- NEWS ResMed (RMD) Could Be 14% Undervalued On Its Sleep Health Growth Story - simplywall.st — simplywall.st positive
- NEWS ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch — MarketWatch positive
- NEWS ResMed Inc. stock rises Wednesday, outperforms market - marketwatch.com — marketwatch.com positive
- NEWS BofA Securities Maintains ResMed(RMD.US) With Buy Rating, Maintains Target Price $320 - Moomoo — Moomoo positive
- NEWS ResMed (RMD) Q2 2026 Earnings: EPS Beats Estimates, Stock Rises 2.9% - EPS Miss Report - dars.gov.et — dars.gov.et positive
Generated 2026-09-14T05:21:58Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMGeographicEurope, Asia and other regions36%10-K Item 1A: 'Sales in combined Europe, Asia and other regions accounted for approximately 36% and 36% of our net revenues in the ... years ended June 30, 2025 and June 30, 2024, respectively.'
- HIGHGeographicmanufacturing outside the U.S.10-K Item 1A: 'We manufacture substantially all of our products outside the U.S. and sell a significant portion of our products outside the U.S.'
Material Events(8-K, last 90d)
- 2026-04-30Item 5.02MEDIUMCFO Brett Sandercock will retire from the CFO role effective May 4, 2026, becoming Special Advisor to the Chairman/CEO through 2027; retirement not due to any disagreement. Aaron Bloomer, former CFO of Exact Sciences, was appointed successor CFO effective May 4, 2026.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $204.24. At $218.27 the A.R:R is 0.3:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $204.24 (Rr Min Solve Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Geographic: manufacturing outside the U.S.; Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Wide-moat business. Accumulate on weakness. Target $221.79 (+1.6%), stop $192.10 (−13.6%), A.R:R 0.3:1. Score 5.7/10, moderate confidence.
Take-profit target: $221.79 (+1.6% upside). Target $221.79 (+1.6%), stop $192.10 (−13.6%), A.R:R 0.3:1. Stop-loss: $192.10.
Concentration risk — Geographic: manufacturing outside the U.S.; Analyst target reached - limited upside remaining; Weak growth.
ResMed Inc. trades at a P/E of 20.9 (forward 16.5). TrendMatrix value score: 5.8/10. Verdict: Buy (Wait for Entry).
27 analysts cover RMD with a consensus score of 3.5/5. Average price target: $246.
What does ResMed Inc. do?ResMed designs cloud-connected medical devices and software to treat obstructive sleep apnea, COPD, and other chronic...
ResMed designs cloud-connected medical devices and software to treat obstructive sleep apnea, COPD, and other chronic respiratory conditions, plus residential-care management software for home health, hospice, and skilled-nursing providers, selling in more than 140 countries with over 10,600 employees. Revenue comes from device sales (CPAP, bilevel, ventilators, masks) and software subscriptions, with more than 30 million patients on its AirView cloud platform and over 10 million registered on myAir.